ArticleMolecular biotechnology2026
Silver Nanoparticles as Antibacterials: Synthesis, Characterization, and Molecular Simulations Against β-Lactamase-Producing Enterobacter and Salmonella spp.
Article in Molecular biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multidrug resistance poses a threat to public health all over the world. Evidences suggest that third-generation antibiotic resistance mediated by extended-spectrum beta-lactamases (ESBLs) in all Enterobacteriaceae species, especially in Enterobacter and Salmonella. In this study, silver nanoparticles (AgNPs) were synthesized and characterized using sol-gel synthesis and powder X-ray diffraction. It was shown that clinical isolates were sensitive to AgNPs. The MIC and MBC, time-dependent growth inhibition test as well as well diffusion agar techniques. ESBL generation was examined using these approaches. There was a low MIC value of 500 μg/ml for Enterobacter and Salmonella. 1000 μg/ml of AgNPs inhibited the development of microorganisms. The antibacterial effect of AgNPs was slow but dependent on concentration and duration. At a concentration of 100 μg/ml, the inhibition zone for Enterobacter was 22 mm, whereas that for Salmonella was 20 mm. Further, molecular docking employed to explore the binding affinity between AgNPs and the active site of beta-lactamase and compare it with reference. Results revealed a very strong score (- 26.79 kcal/mol). Next, MD simulation was performed. The MD simulation results showed a stable interaction between beta-lactamase-nanocluster. Experimental and computational results elucidate the molecular mechanism of anti-bacterial activity of AgNPs to fight against bacterial infections.
Indexed as
Identifiers
40329120What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.